Table 1 Overview of patient and treatment characteristics of included treatment trajectories.
From: Bayesian network analysis of antidepressant treatment trajectories
Variable | PG (n = 4808) | UMCU (n = 735) |
|---|---|---|
Mean (sd) or proportion | Mean (sd) or proportion | |
Follow-up from start prescription (days) | 1175 (804) | 52.7 (59.8) |
Age | 48.42 (17.97) | 43.861 (17.02) |
Sex: female | 0.577 | 0.615 |
Prescription group:Â MAOI | 0.013 | 0.061 |
Prescription group:Â other | 0.047 | 0.020 |
Prescription group:Â SSRI | 0.467 | 0.430 |
Prescription group:Â nSSRI | 0.161 | 0.200 |
Prescription group:Â TCA | 0.177 | 0.261 |
Prescription group:Â TetraCA | 0.172 | 0.060 |
Benzodiazepine prescription | 0.643 | 0.848 |
Lithium prescription | 0.081 | 0.165 |
Antipsychotics prescription | 0.423 | 0.574 |
Disulfiram prescription | 0.015 | 0.003 |
DSM: Depression | 0.401 | 0.571 |
DSM: Personality disorder | 0.268 | 0.242 |
DSM: Anxiety disorder | 0.077 | 0.125 |
DSM: Social problems | 0.025 | 0.211 |
GAF score at start treatment | 48.03 (9.463) | 33.33 (13.56) |
Medication trajectory duration (days) | 162.7 (234.1) | 109.4 (236.0) |
Continuation of antidepressant | 0.663 | 0.894 |
Mean change sentiment core complaints |  − 0.152 (0.752) |  − 0.206 (0.703) |
Mean change sentiment social functioning | 0.321 (0.698) | 0.464 (0.696) |
Mean change sentiment well-being | 0.293 (0.618) | 0.162 (0.696) |
Mean change sentiment experience |  − 0.094 (0.681) |  − 0.160 (0.590) |
